58
Participants
Start Date
August 4, 2014
Primary Completion Date
May 18, 2021
Study Completion Date
May 18, 2021
Emapalumab
Treatment with emapalumab is not planned for all enrolled participants. For participants who will continue receiving emapalumab in the context of this study (NI-0501-05), the dose and timing will be either carried forward from the last administered emapalumab dose as part of the parent study in which the participant was enrolled, or an adjusted dose will be administered, if necessary.
Fondazione MBBM c/o Ospedale San Gerardo Clinica Pediatrica, Monza
University of North Carolina at Chapel Hill, Chapel Hill
Hospital Universitario Niño Jesús Servicio de Hemato-Oncología Pediátrica, Madrid
Azienda Ospedaliera Padova, Padua
Ospedale della Donna e del Bambino - U.O.C. Oncoematologia Pediatrica, Verona
Cincinnati Children's Hospital, Cincinnati
Spectrum Health Helen Devos Children's Hospital, Grand Rapids
Hôpital Necker-Enfants Malades, Paris
Texas Children's Cancer Center, Houston
Cincinnati Children's Hospital - Division of Immunobiology, Cincinnati
Ospedale Pediatrico Bambino Gesu - UO Reumatologia, Rome
Ospedale Pediatrico Bambino Gesu, Rome
Hospital Universitario Vall d'Hebron Servei de Hematologia i Oncologia, Barcelona
Sant Joan de Déu Hospital - Pediatric Rheumatology Department, Barcelona
UCL Institute of Child Health Great Ormond Street Hospital, London
Great Ormond Street Hospital - Department of Haematology, London
Lead Sponsor
Seventh Framework Programme
OTHER
Swedish Orphan Biovitrum
INDUSTRY